An integrated systems pharmacology platform for pharmacogenomic research

Information

  • Research Project
  • 7877781
  • ApplicationId
    7877781
  • Core Project Number
    R43GM087839
  • Full Project Number
    5R43GM087839-02
  • Serial Number
    87839
  • FOA Number
    PAR-07-160
  • Sub Project Id
  • Project Start Date
    7/1/2009 - 15 years ago
  • Project End Date
    6/30/2011 - 13 years ago
  • Program Officer Name
    OKITA, RICHARD T.
  • Budget Start Date
    7/1/2010 - 14 years ago
  • Budget End Date
    6/30/2011 - 13 years ago
  • Fiscal Year
    2010
  • Support Year
    2
  • Suffix
  • Award Notice Date
    8/2/2010 - 14 years ago
Organizations

An integrated systems pharmacology platform for pharmacogenomic research

DESCRIPTION (provided by applicant): The goal of this project is to develop a database and functional genomic analysis platform specifically designed for the study of the biological consequences of mutations and sequence heterogeneity in human genes and their controlling regions. The product will comprise i) a comprehensive database of known single nucleotide polymorphisms (SNPs), splice variants, translocations, copy number changes, and other alterations in genetic sequence that change the sequence, transcription or translation of human, rat or mouse proteins;ii) a comprehensive knowledgebase of literature-reported associations between human, rat and mouse sequence heterogeneities and the functional consequences of those differences to protein levels, protein stability and half life, enzymatic activity, substrate specificity, protein complex formation, protein-protein and protein-compound interactions, transcription factor activity or any other characteristic of biological consequence;iii) a suite of software tools, building on the GeneGo MetaDiscovery platform. This product, by combining knowledge on the functional consequences of sequence variations with a best- in-class systems biology software platform, will be unique in the marketplace. The product will allow the user to search for known sequence variations and their functional effects, identify metabolic and signaling networks within which the altered proteins are acting, and to categorize diseases and adverse drug effects associated with sequence variations. The user will be able to quickly identify potential strategies and targets for therapeutic interventions to combat increased vulnerability to disease or toxicity, find alternative therapeutic approaches to avoid sequence-related altered pharmacology or absorption, distribution, metabolism, elimination or toxicity parameters (ADMET), identify biomarkers of adverse effects associated with sequence variations. The product will smooth the progress "personalized medicine" by facilitating the application of personal genetic profiles to identify optimal therapeutic strategies for illness and disease. This will be an invaluable tool for disease research, pharmaceutical discovery, toxicology and clinical medicine. It will market and sold by GeneGo as part of the MetaDiscovery suite of products.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    143710
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:143710\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    GENEGO, INC.
  • Organization Department
  • Organization DUNS
    113429489
  • Organization City
    ST. JOSEPH
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    490852175
  • Organization District
    UNITED STATES